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Abstract
Coronavirus disease 2019 (COVID-19) has become a major, global, public health challenge. Over 1,051,635 confirmed cases have been reported worldwide,
and both local and international travelers are considered to represent populations at high risk of acquiring the infection. Many factors are involved in the
spread of this viral agent, including travel to and from endemic areas, a history of contact with a traveler from an endemic country, the virus infection rate at
the destination, individual health, and inadequate prevention and control measures. The virus is thought to be transmitted through respiratory droplets, gen-
erated by coughing or sneezing and spread through close contact with infected persons or contaminated surfaces. Diagnostic strategies include detection of
antiviral antibodies, multiplex nucleic acid amplification, and microarray-based assays. Currently, no approved antiviral therapy or vaccine exists to treat or
prevent the infection. Public health measures have been enforced, to slow spread of the virus, by governments. The World Health Organization (WHO) have
recommended screening be performed at airports, for all travelers, before traveling to endemic countries and the restriction of travel to countries more than
one thousand cases of infection. In response to the global outbreak, this review examines COVID-19 as a potential traveler’s infection.  
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Introduction
Severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) is an enveloped, single-stranded, positive-
sense, ribonucleic acid (RNA) virus that causes corona -
virus disease 2019 (COVID-19), a zoonotic infectious
disease that has been declared a global, public health
emergency of international concern (PHEIC).1,2 The in-
fection was reported to originate from Wuhan, Hubei
Province, China, in 2019, and has been linked to
Wuhan's Huanan Seafood Wholesale Market. Bats are
reportedly the major natural reservoir of the virus, and a
5-year study indicated the coexistence of highly diverse
SARS-CoVs in bat populations found in caves in Yunnan
Province, China.3 A recombination event may have facili -
ta ted the ‘spillover’ from the virus’s original host to a
new host, humans. The viral agent may have been dis-
seminated, from bats to an unknown intermediate host,
followed by the infection of human beings.4,5 The viral
infection has since spread to virtually all parts of the
globe, due to travel and the global migration of infected
and exposed individuals.6 On March 11, 2020, the
World Health Organization (WHO) declared COVID-
19 to be a pandemic, due to its spread to almost all six
WHO regions.7 A reported 1,051,635 (and counting)
confirmed cases have been identified, worldwide, and
both local and international travelers represent popula-
tions at high risk of acquiring the infection.7,8
Coronaviruses usually cause mild respiratory infections;
however, the symptoms of SARS-CoV-2 infections can
range from mild, including fever, cough, and difficulty
breathing, to severe, causing pneumonia and multi-organ
failure. Elderly individuals and individuals with pre-ex-
isting medical conditions are at high risk of progressing
speedily and swiftly into acute respiratory distress syn-
drome, septic shock, and coagulation dysfunction, which
can result in death.1 This review examines SARS-CoV-2
infect ions and COVID-19 as a potential traveler’s dis-
ease.
The Structure of Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2)
SARS-CoV-2 also known as 2019-nCoV,2 is an en-
veloped, single-stranded, positive-sense RNA virus, with
a 3’-poly-A tail and a 5′-cap structure. The name corona -
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virus derives from the crown-like characteristic appear-
ance under electron microscopy (corona is the Latin term
for crown), due to the presence of spike glycoproteins on
the envelope 9 (Figure1).
SARS-CoV-2 is a strain of SARS-related coronavirus-
es, from the taxonomic perspective. SARS-CoV-2 be-
longs to the family Coronaviridae, in the genus
Betacoronavirus.11 The genetic material found in SARS-
CoV-2 is approximately 30 kb in length, which makes it
the largest known genome that has been identified in an
RNA virus. The SARS-CoV-2 virus is one of seven
Coronaviridae capable of infecting human beings, in ad-
dition to NL63, HKU1, 229E, OC43, MERS-CoV, and
SARS-CoV.12,13 The genome of a typical coronavirus
contains a minimum of six open-reading frames (ORFs).
Approximately 70% of the viral genome encodes the
polyprotein pp1ab, which is further cleaved into 16 non-
structural proteins, which play roles in genome replica-
tion and transcription through the viral-encoded chy-
motrypsin-like protease (3CLpro), in synergy with one
or two papain-like proteases.14,15 The other 30% of the
genome encodes four structural proteins, including spike
(S), envelope (E), membrane (M), and nucleocapsid (N),
and additional helper proteins. The S protein plays a sig-
nificant role, mediating membrane fusion and receptor
binding, which, in turn, determines the host tropism of
the virus.16,17
Transmission Routes and Diagnosis of COVID-19
Epidemiological studies in Wuhan were the first out-
break was reported, associated the virus with a sea food
market where live animals were sold, with many patients
having worked in, or visited the market.4,5 Sub sequently,
secondary cases begun to appear approximately ten days
later.18 Although the new patients had no direct contact
with the seafood market, contact tracing showed that
they had contacts with inhabitants near the market.19
Advanced genetic and virologic studies have found that
bats represent natural reservoirs of this viral agent.4,20
Studies have demonstrated that most bat CoVs have simi -
lar genomes as those found in beta-CoVs and alpha-
CoVs.19,21
The virus can be identified through different labora-
tory methods, including the rapid testing of
Immunoglobulin G (IgG) and Immunoglobulin M (IgM)
levels, electron microscopy, cell-culturing, and nucleic
acid detection reverse transcriptase-polymerase chain re-
action (RT-PCR), which is currently the gold standard
for SARS-CoV-2 testing and is performed on a nasopha-
ryngeal sample. When an individual is confirmed to be
infected, contact tracing is performed, during which a de-
tailed history of all persons in contact with a confirmed
patient is examined, using precise laboratory testing.1,22
SARS-CoV-2 infections can also be determined by a myr-
iad of clinical features, predictors, a chest computed to-
mography (CT) scans showing pneumonia characteristics
and others.23,24 As of March 19, 2020, no antibody-
based techniques have been developed, although serious
ongoing studies are attempting to develop these tech-
niques.22
Clinical Features of SARS-CoV-2 Infection
The viral agent gains entry into the respiratory tract
and infects the cells of the respiratory system,25,26 caus-
ing acute respiratory disease, with a high prevalence
among travelers.27 The incubation period for the viral
infection is approximately 2–14 days, with an average in-
cubation period of 5 days.19 The infection is usually
asymptomatic among those with a travel history to en-
demic countries, but can also present with symptoms
similar to those observed during flu infections, including
fever, dry cough, and difficulty breathing.14,28 When
these symptoms are present, the difficulty breathing and
associated chest pain and pressure persists, resulting in
walking difficulties, confusion, and a bluish tint to the
lips and face. These symptoms indicate a critical situation
that requires immediate medical attention.14,29 Zhang,
et al.,22 reported the presence of the virus in fecal and
blood samples, suggesting the possibility of multiple
transmission routes. The identification of the viral recep-
tor, angiotensin-converting enzyme 2 (ACE2), which is
often present in large quantities on enterocytes in the
small intestines and epithelial cells in the lung alveoli, is
likely to assist researchers in understanding infection
routes and the pathogenesis of the viral agent.30
Figure 1. SARS-CoV-2 Morphology with the Minimal Set of Structural
Proteins 9-10
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Aspects of COVID-19 Epidemiology as a Traveler’s
Infection
In December 31, 2019, the novel SARS-CoV-2 out-
break was first reported in Wuhan City, Hubei Province,
China,31 as pneumonia outbreak without a known causal
agent. The WHO announced that the etiology was a new
coronavirus, which was temporarily referred to as2019-
nCoV, and was posited to be the causal agent for the in-
fection on January 12, 2020.32 Similar to SARS, the
COVID-19 outbreak is thought to have initiated at a local
seafood market, the Huanan Seafood Wholesale Market,
and 2/3 of the first 41 confirmed cases were linked to the
market. Within a few weeks, the virus had spread to oth-
er countries, including those in Europe. Most SARS-
CoV-2 cases reported during the first 6 days (January 23–
28, 2020) were associated with direct contact with some-
one who traveled to or from Wuhan.33 In Germany, a
33-year-old man (patient 1) became ill with cold and flu
symptoms, on January 24, 2020, after attending a meet-
ing in Munich with a Chinese business partner, on
January 20, 2020.21 The business partner was visiting
from Shanghai and she did not experience any signs or
symptoms of illness. In Italy, a Bayesian phylogenetic re-
construction suggested that the virus found in Italy was
imported by Chinese travelers, who were infected before
they arrived in Italy.34 Japan identified its first case of vi-
ral infection on January 16, 2020, associated with a
Chinese traveler from Wuhan.35 Australia’s first case was
identified on January 25, 2020, associated from a man
who traveled to Wuhan.36 On January 20, 2020, the USA
identified its index case, a traveler who returned from
Wuhan, China.37 On January 24, 2020, France identified
its first confirmed case of the novel coronavirus, which
was also connected with a travel history to China.38 A
traveler from Wuhan and Qom imported the first case of
the infection from China to Iran on January 19, 2020.39
The index case for Pakistan was identified on February
26, 2020, when a young man with travel history to
Karachi tested positive for the virus.40 On March 10,
2020, Turkey reported its index case, in a Turkish male
who traveled to Europe.41 The initial report of viral in-
fection in South Africa was March 5, 2020, in a patient
who had traveled to Italy with his wife.42 The WHO has
reported that the median age of people testing positive
for the virus was approximately 45 years and that over
two-thirds of those infected were males.18 The mortality
rate among confirmed positive cases was 4.5%, as of
March 25, 2020, and appears to range from 0.2%–15%,
depending on age group and other health-related
factors.18 The fatality rates differ among countries and
over time, based on differences in the rate of diagnosis
and due to differences in access to adequate healthcare
workers and facilities.
Prevention and Control of SARS-CoV-2 Infection
Preventive measures that have been implemented
against the spread of the novel coronavirus include stay-
ing at home, practicing social distancing (avoiding
crowded places), washing hands with soap and running
water, regularly, for at least 20 seconds, good personal
hygiene practices and the avoidance of picking or touch-
ing the nose, eyes, mouth, and other parts of the face
with unwashed hands.43-45 Recommendations by the
Centers for Disease Control and Prevention (CDC) in-
cluded covering the nose and mouth with tissues when
sneezing or coughing or using the inside of the elbow
when tissue availability is scarce.46 Social distancing,
which refers to people remaining at least 6 feet apart
from one another, was introduced to reduce contact be-
tween people carrying the virus and uninfected popula-
tions. Workplaces and schools were closed, travel
restrict ions were implemented, and mass gatherings of
more than 50 individuals were canceled.47 According to
the WHO and CDC, surgical masks should only be used
when an individual is symptomatic or is administering
care to infected or suspected-infected persons, such as
health workers.43,44
Measures that benefit the community, such as the can-
cellation of mass gatherings, social distancing, the closing
of schools, and the creation of plans that allow employees
to work from home can help mitigate the dissemination
of SARS-CoV-2 infections, and these types of preventive
measures have been recommended by different CDC
agencies, worldwide.46,47 Public health experts should
provide travelers with information and guidelines regard-
ing how they can mitigate their overall risks of viral in-
fections and other respiratory complications, which can
be disseminated through travel agencies, conveyance o -
perators, travel health clinics, and at points of entry.46
Possible Treatments and Vaccine Candidates for
COVID-19 Infection
A variety of treatment methods and antiviral agents
are being explored for the potential treatment of SARS-
CoV-2 infections, and some are progressing to the clini-
cal trial stage.48 WHO has launched “Solidarity”, which
is a multi-country trial including 10 countries, in res -
ponse to the COVID-19 pandemic, on March 2020.44
The following drugs are being studied: chloroquine and
hydroxychloroquine, ritonavir / lopinavir and remdesivir
in synergy with beta interferon.45,49 Scientific reports e -
xist showing that remdesivir can be used to treat the viral
infection,50 because it inhibits SARS-CoV-2 RNA tran-
scription, in vitro. 
Chloroquine, a drug that is currently used to treat
malaria, is another potential drug that is currently being
tested in China, with positive preliminary evidence.4,51
Chloroquine and hydroxychloroquine can effectively stop
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the effects of the viral agent, in vitro, and hydroxychloro-
quine has been shown to be more potent than chloro-
quine, with a more tolerable safety profile.47 Chloroquine
and hydroxychloroquine have been listed as drugs with
good preliminary outcomes for COVID-19 therapy, by
the Italian Pharmaceutical Agency (IPA) in March 17,
2020.46,52
Currently, no vaccines are available for SARS-CoV-2
infections; however, vaccine development is crucial for
inducing herd immunity and the possible eradication of
this disease.43 Various ongoing studies are examining
mRNA, epitope, and S protein-RBD structure-based vac-
cine candidates. Models of the human ACE2 protein in
transgenic mice and rhesus monkeys have been well-
mapped for the creation of a vaccine, and some SARS-
CoV-2 vaccines candidates are already entering the clini -
cal trial stage.53 In Seattle, USA, the first human trials
for a vaccine candidate began on March 16, 2020, with
just four volunteers.54 The vaccine candidate contains a
harmless genetic code, copied from the SARS-CoV-2
virus that causes disease. Recombinant interleukin-7 (IL-
7) therapy is also being investigated, as this protein plays
a significant function in the reproduction and maturation
of lymphoid cells.55
Conclusion
Global migration, changes in climate, and evolving
human-animal interactions are possible factors that may
enhance the COVID-19 pandemic. Travelers are at high
risk of acquiring the infection, and most countries with
high numbers of cases have placed travel bans on foreign
travel. We have provided a summarized review of the
COVID-19 pandemic as a potential agent for traveler’s
infections, worldwide.
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